Category Archives: Neuroscience

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market, Trends, Analysis, Opportunities, Share and Forecast 2019-2025 – Digits N Markets News

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market to reach USD 5.1 billion by 2025. The increasing automation of high-throughput screening and the availability of robust data management software tools, which enable researchers to develop systemic and process-oriented approaches toward neuroscience antibodies and assays techniques are some of the factors contributing to the growth of this segment.

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market valued approximately USD 2.1 billion in 2016 is anticipated to grow with a healthy growth rate of more than 10.3% over the forecast period 2017-2025

To request a sample copy or view summary of this report, click the link below: http://digitsnmarkets.com/sample/5594-global-neuroscience-antibodies-and-assays-market

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market.

Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product

By Technology

By End-User

Some of the key manufacturers involved in the market are. Thermo Fisher Scientific, Abcam, Bio-Rad, Merck KGAA, Cell Signaling Technology, Genscript, Rockland Immunochemicals. Bio Legend, Santa Cruz Biotechnology, Tecan, F. Hoffmann-La Roche, Siemens. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

About Digits N Markets:

Digits N Markets has a vast repository of latest market research reports on trending topics, niche company profiles, market size and other relevant data released by renowned publishers. We have access to the database related to niche markets and trending topics in various industries. We also update the data regularly to provide recent statistics to the client. Recent data and reports will be featured on our websites and clients will be able to access the same. Our clients will be able to benefit from qualitative & quantitative insights in the report which will support them in taking concrete business decisions.

Contact Us :Digits N Markets 410 E Santa Clara Street, Unit #762San Jose, CA 95113Phone :+1 408-622-0123Email: sales@digitsnmarkets.comWebsite:- http://www.digitsnmarkets.com

Read the original here:
Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market, Trends, Analysis, Opportunities, Share and Forecast 2019-2025 - Digits N Markets News

Neuroscience Antibodies & Assays Market 2020 : Global Analysis On Key Companies Like Roche Ltd, Thermo Fisher Scientific And Industry Forecast By…

Neuroscience antibodies & assays market is anticipated to grow with a significant rate in the coming years, owing to the increasing incidence of neurological disorders, growing pharmaceutical & biotechnology industries and increasing investments in neuroscience research. On the other hand, increasing research & development activities are projected to offer novel growth opportunities for the players operating in the neuroscience antibodies & assays market, in the coming years

Neuroscience involves the study of nervous system, where the research is completely relies on assays and antibodies. These antibodies and assays are specific that helps to identify and examine reactions on the cellular, biochemical and molecular level. Antibody-based approaches are used for the localization, isolation and characterization of targeted proteins that majorly used in the cellular and molecular neuroscience. On the other hand, the use of assays provide an efficient, valuable solution for determination of critical targets that are involved in synaptic signaling, neural development and neurodegeneration.

Get Sample PDF of thisReport@https://www.theinsightpartners.com/sample/TIPBT00002234/

Global Neuroscience Antibodies & Assays Market Analysis to 2027 is a specialized and in-depth study with a special focus on the global medical device market trend analysis. The report aims to provide an overview of neuroscience antibodies & assays market with detailed market segmentation by product, technology, application, end user and geography. The global neuroscience antibodies & assays market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading neuroscience antibodies & assays market players and offers key trends and opportunities in the market.

Below mentioned is the list of few companies engaged in the neuroscience antibodies & assays market:-

As, The report also includes the profiles of key neuroscience antibodies & assays market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Key developments in the neuroscience antibodies & assays market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from neuroscience antibodies & assays market are anticipated to lucrative growth opportunities in the future with the rising demand for neuroscience antibodies & assays in the global market.

The global neuroscience antibodies & assays market is segmented:-on the basis of product, technology, application and end user. Based on product, the market is segmented as consumables and instruments. On the basis of technology, the global neuroscience antibodies & assays market is segmented into molecular diagnostics, clinical chemistry, immunoassays/immunochemistry and others. Based on application, the market is segmented as in vitro diagnostics, research and drug discovery. Based on end user, the market is segmented as hospitals & diagnostics centers, academic & research institutes and pharmaceutical & biotechnology companies.

e report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global neuroscience antibodies & assays market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The neuroscience antibodies & assays market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting neuroscience antibodies & assays market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the neuroscience antibodies & assays market in these regions.

Buy thisReport@https://www.theinsightpartners.com/buy/TIPBT00002234/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

We are committed to providing highest quality research and consulting services to our customers. We help our clients understand key market trends, identify opportunities, and make informed decisions by providing market research solutions at an affordable cost.

Contact us:

The Insight partners,

Phone: +1-646-491-9876

Email:sales@theinsightpartners.com

Read the rest here:
Neuroscience Antibodies & Assays Market 2020 : Global Analysis On Key Companies Like Roche Ltd, Thermo Fisher Scientific And Industry Forecast By...

Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning – Business Wire

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimers disease (AD) and other neurodegenerative disorders, announced today that Peter N. Laivins, MBA, has been appointed Head of Commercial Strategy and Planning. Mr. Laivins brings more than 20 years of leadership in the biopharmaceutical industry, with broad expertise in business strategy and commercialization for Alzheimers therapies, including his experience at Pfizer launching ARICEPT for symptomatic treatment for AD and at Elan Biopharmaceuticals leading commercial strategy for bapineuzumab as an anti-amyloid immunotherapy for AD.

Peter brings unparalleled depth of business and commercial expertise to Alzheon, with a unique track record of shaping the Alzheimers commercial landscape and a career-long passion to fight this debilitating disease, said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon. Peters skills will be invaluable as we move our lead drug ALZ-801 into Phase3 trials and prepare for future commercialization of potentially the first oral and well tolerated disease-modifying treatment for millions of Alzheimers patients and their families.

Most recently, Mr. Laivins was the Senior Vice President of Strategic Development Program Leadership at Tesaro, Inc., with oversight of five development teams, portfolio management and competitive intelligence. Previously, at Merrimack Pharmaceuticals, he served as Senior Vice President and Head of Late Stage Development, where he led the successful clinical development, NDA submission and FDA approval of Onyvide the first new therapy for pancreatic cancer in two decades. Mr. Laivins career in neuroscience drug development includes his role as Vice President of Strategic Brand Management for Elan Biopharmaceuticals, with responsibility for the Alzheimers portfolio, including bapineuzumab, and the multiple sclerosis portfolio, including TYSABRI. At Pfizer, Mr. Laivins held positions of increasing responsibility, including the Global Team Leader in Neuroscience, leading the launch of Aricept which achieved peak sales exceeding $3 billion. Beyond neuroscience, he also served as Group Leader for US Oncology Marketing at Pfizer. Mr. Laivins is a graduate of McGill University with a Bachelor of Science in microbiology and immunology and Master of Business Administration.

Im excited to join the team at Alzheon at this important juncture in Alzheimers drug development. Last year we saw convincing clinical validation of anti-amyloid therapy, which confirmed that targeting amyloid toxicity can slow disease progression and provide clinical improvement in patients, said Mr. Laivins. We believe ALZ-801 could be transformative as the first oral disease modifying treatment for Alzheimers and provide an important advance for patients and their families.

About ALZ-801

Alzheons lead product candidate, ALZ-801, an oral anti-amyloid drug candidate that is an optimized prodrug of tramiprosate, has shown promising results in analyses of clinical data1,2 and a novel therapeutic mechanism of action.3 ALZ-801 has received Fast Track designation from the U.S. Food and Drug Administration. The clinical data for ALZ-8014 and its active agent, tramiprosate, suggest long-term clinical efficacy in AD patients with the apolipoprotein E4 (APOE4) genotype and a favorable safety profile.1,2 ALZ-801 acts through a novel enveloping molecular mechanism of action blocking the formation of toxic amyloid oligomers3 associated with the development and progression of AD.6 The cognitive improvements observed in AD patients in the tramiprosate Phase 3 studies may be attributed, in part, to the therapeutic anti-oligomer action of 3-sulfopropanoic acid (3-SPA), an endogenous substance in the human brain, discovered by Alzheon scientists, that inhibits the formation of neurotoxic beta amyloid oligomers.5 3-SPA is the primary metabolite of ALZ-801 in humans and its discovery elucidates the beneficial pharmaceutical attributes of ALZ-801, including a favorable safety profile, selectivity against beta amyloid oligomers, and excellent brain penetration. ALZ-801 increases levels of 3-SPA in the brain and augments the bodys natural mechanism for blocking the formation of toxic amyloid oligomers.5 The initial Phase 3 program for ALZ-801 will focus on patients with the homozygous APOE4/4 genotype at the Early stage of AD, with the potential for future expansion to additional Alzheimers populations.6

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimers clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of beta amyloid aggregation and neurotoxicity hallmarks of Alzheimers disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimers patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.

Alzheon Publications1Abushakra et al. Journal of Prevention of Alzheimers Disease, 20162Abushakra et al. Journal of Prevention of Alzheimers Disease, 20173Kocis et al. CNS Drugs, 20174Hey et al. Clinical Pharmacokinetics, 20185Hey et al. CNS Drugs, 20186Tolar et al. Alzheimers & Dementia, 2019

Original post:
Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning - Business Wire

The 13 Universal Emotions Evoked by Music – Technology Networks

The Star-Spangled Banner stirs pride. Ed Sheerans The Shape of You sparks joy. And ooh l l! best sums up the seductive power of George Michaels Careless Whisper.

UC Berkeley scientists have surveyed more than 2,500 people in the United States and China about their emotional responses to these and thousands of other songs from genres including rock, folk, jazz, classical, marching band, experimental and heavy metal.

The upshot? The subjective experience of music across cultures can be mapped within at least 13 overarching feelings: Amusement, joy, eroticism, beauty, relaxation, sadness, dreaminess, triumph, anxiety, scariness, annoyance, defiance, and feeling pumped up.

Imagine organizing a massively eclectic music library by emotion and capturing the combination of feelings associated with each track. Thats essentially what our study has done, said study lead author Alan Cowen, a UC Berkeley doctoral student in neuroscience.

We have rigorously documented the largest array of emotions that are universally felt through the language of music, said study senior author Dacher Keltner, a UC Berkeley professor of psychology.

Cowen and fellow researchers have translated the data into an interactive audio map where visitors can move their cursors to listen to any of thousands of music snippets to find out, among other things, if their emotional reactions match how people from different cultures respond to the music.

Potential applications for these research findings range from informing psychological and psychiatric therapies designed to evoke certain feelings to helping music streaming services like Spotify adjust their algorithms to satisfy their customers audio cravings or set the mood.

While both U.S. and Chinese study participants identified similar emotions such as feeling fear when hearing the Jaws movie score they differed on whether those emotions made them feel good or bad.

People from different cultures can agree that a song is angry but can differ on whether that feeling is positive or negative, said Cowen, noting that positive and negative values, known in psychology parlance as valence, are more culture-specific.

Across cultures, study participants mostly agreed on general emotional characterizations of musical sounds, such as anger, joy and annoyance. But their opinions varied on the level of arousal, which refers in the study to the degree of calmness or stimulation evoked by a piece of music.

How they conducted the study

For the study, more than 2,500 people in the United States and China were recruited via Amazon Mechanical Turks crowdsourcing platform.

First, volunteers scanned thousands of videos on YouTube for music evoking a variety of emotions. From those, the researchers built a collection of audio clips to use in their experiments.

Next, nearly 2,000 study participants in the United States and China each rated some 40 music samples based on 28 different categories of emotion, as well as on a scale of positivity and negativity, and for levels of arousal.

Using statistical analyses, the researchers arrived at 13 overall categories of experience that were preserved across cultures and found to correspond to specific feelings, such as depressing or dreamy.

To ensure the accuracy of these findings in a second experiment, nearly 1,000 people from the United States and China rated over 300 additional Western and traditional Chinese music samples that were specifically intended to evoke variations in valence and arousal. Their responses validated the 13 categories.

Vivaldis Four Seasons made people feel energized. The Clashs Rock the Casbah pumped them up. Al Greens Lets Stay Together evoked sensuality and Israel (Iz) Kamakawiwooles Somewhere over the Rainbow elicited joy.

Meanwhile, heavy metal was widely viewed as defiant and, just as its composer intended, the shower scene score from the movie Psycho triggered fear.

Researchers acknowledge that some of these associations may be based on the context in which the study participants had previously heard a certain piece of music, such as in a movie or YouTube video. But this is less likely the case with traditional Chinese music, with which the findings were validated.

Cowen and Keltner previously conducted a study in which they identified 27 emotions in response to visually evocative YouTube video clips. For Cowen, who comes from a family of musicians, studying the emotional effects of music seemed like the next logical step.

Music is a universal language, but we dont always pay enough attention to what its saying and how its being understood, Cowen said. We wanted to take an important first step toward solving the mystery of how music can evoke so many nuanced emotions.

Reference

Cowen et al. (2020) What music makes us feel: At least 13 dimensions organize subjective experiences associated with music across different cultures. PNAS. DOI: https://doi.org/10.1073/pnas.1910704117

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read this article:
The 13 Universal Emotions Evoked by Music - Technology Networks

VoxNeuro Announces Research Project With St. Joseph’s Healthcare Hamilton – Business Wire

HAMILTON, Ontario--(BUSINESS WIRE)--At the close of 2019, VoxNeuro joined a pilot study conducted by the Womens Health Concerns Clinic & Mood Disorders Program at St. Josephs Healthcare Hamilton. The study is led by Dr. Benicio Frey and Dr. Flavio Kapczinski, and has been designed to identify biomarkers of bipolar disorder.

Dr. Frey, the studys Principal Investigator, is the Academic Head of the Mood Disorders Program, and is the Medical Director of the Womens Health Concerns Clinic at St. Joseph's Healthcare. He also holds the position of Associate Professor at the Department of Psychiatry and Behavioural Neurosciences at McMaster University. Specializing in psychiatry, biochemistry and brain imaging in bipolar disorder, Dr. Frey has more than 150 articles published in peer-reviewed journals.

Dr. Kapczinski, Psychiatrist at St. Josephs Healthcare Hamilton, professor and Director of the Neuroscience Graduate Program at McMaster University, is a leading author in the area of mood disorders and has published over 430 peer-reviewed articles (over 22,000 citations). Dr. Kapczinski and colleagues helped to develop the concepts of neuroprogression and staging in bipolar disorder, published in 2009. This current study intends to add objective details to Dr. Kapczinskis staging model by assessing whether the brains connectivity alterations are associated with illness progression in bipolar disorder.

Dr. Kapczinski was an early supporter of VoxNeuros work, founded on the lifetime research of Dr. John F. Connolly, a colleague of Dr. Kapczinski at McMaster University and VoxNeuros Chief Science Officer. In an interview in the fall of 2017, Dr. Kapczinski spoke to the potential of VoxNeuros Cognitive Health Assessments and the impact they will have on both brain injuries and mood disorders, If someone is having depressive symptoms but then we think the origin is actually repeated brain injuries, having a tool that can confirm that can put us on the right trackHaving an objective measurement related to the brain function of people who have suffered traumatic brain injuries is enormous, clinically.

For this project, the teams are collaborating on the assessments application to mood disorders, specifically bipolar. The current classifications of psychiatric diagnoses are based purely on behavioural observation and self-report, and lack of substantial biological validation. This contrasts sharply with the rest of medicine where diagnosis and treatment are routinely aided by biological tests that are based on validated biomarkers. Biological markers, or biomarkers, are quantitative measurements that provide information about biological processes, a disease state, or about response to treatment (FDAs Biomarkers Research Group definition). The objective of the study is to create a biological bank of potential biomarkers to investigate etiology, prognosis, and/or treatment response in individuals with bipolar disorder.

VoxNeuros Cognitive Health Assessments are being used alongside blood tests and various behavioural and clinical assessments to identify the most effective tools to accurately predict onset, diagnose, inform prognoses and track treatment responses for bipolar disorder. Specifically, in addition to the objective reports provided by VoxNeuros Cognitive Health Assessments, the EEG data is being used to investigate functional connectivity patterns as a potential biomarker for bipolar disorder. A recent review showed that abnormal fronto-cortical connectivity may be involved in bipolar disorder across mood states. These connectivity disturbances possibly contribute to emotional dysregulation, and cognitive impairments in bipolar disorder.

If the pilot study results support the hypothesis, a follow-on multi-year longitudinal study will be pursued to widen the data, track participants throughout diagnoses & treatment, and assess the accuracy of prognoses. This is one of VoxNeuros first examples of being integrated into a clinical study to provide objective measures to guide the examination of researchers hypotheses.

Were looking forward to working closely with St. Josephs Healthcare and St. Joes Research Institute on this project. Its a perfect example of the strong opportunities that exist between VoxNeuro, other innovative healthcare startups being built in this region, and the industry leading healthcare teams right here in our own backyard. Spinning our technology out of McMaster University, were extremely fortunate to be headquartered in Hamilton Canadas leading health sciences research cluster, says Kimberly Elliott, COO of VoxNeuro.

Read the original:
VoxNeuro Announces Research Project With St. Joseph's Healthcare Hamilton - Business Wire

BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia -…

Foundational study with plans to address multiple types of agitation associated with dementia

Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders

Topline results expected in mid-2020

NEW HAVEN, Conn., Jan. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that the first patient has been enrolled in a Phase 1b/2 study of BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex), for the acute treatment of agitation in patients with dementia.

We are excited to advance the clinical development of BXCL501 in agitation associated with dementia, a third potential indication for our lead product candidate, commented Robert Risinger, M.D., Vice President, Clinical Development of BTAI. With no approved treatments, there is a significant need for better treatment options for the 6 million patients in the U.S. with dementia, many of whom will experience agitation during the course of their disease. We believe our candidate, BXCL501, with its unique mechanism and convenient oral dosing, has the potential to rapidly reduce agitation associated with dementia without excessive sedation or other undesired side effects. This study builds upon the foundation for a broad BXCL501 program in dementia, including the treatment of chronic agitation and the prevention of agitation using a wearable device in combination with BXCL501.

The multicenter, randomized, double-blind, placebo-controlled, ascending dose Phase 1b/2 study is designed to evaluate the efficacy, pharmacokinetics, safety and tolerability of BXCL501 in adults 65 years and older who exhibit acute agitation associated with all forms of dementia, including Alzheimer's disease. The dementia program expands on the Phase 1b study performed with BXCL501 in 135 patients with agitation associated with schizophrenia, and also builds on the positive results observed in reducing agitation with intravenous Dex in Alzheimers disease patients. This is an adaptive design and is expected to assess multiple dose cohorts of BXCL501 or matching placebos. Following the completion of each dose cohort, a safety and tolerability review is expected to be performed to determine the next tested dose. The study is designed to assess agitation as measured by the Pittsburgh Agitation Scale, a validated clinical instrument, as well as improvement in the modified Cohen Mansfield Agitation Inventory and Positive and Negative Syndrome Scale, Excitatory Component (PEC).

About BXCL501

BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of agitation.

A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in a Phase 1b/2 trial for the treatment of agitation associated with dementia.

About Agitation Associated with DementiaDementia is a neurocognitive condition caused by damage to brain cells that leads to a decline in cognitive abilities and independent function. It affects approximately 6 million individuals in the United States, with Alzheimers disease accounting for 60-70% of these cases. During the course of the disease, patients with dementia often suffer from psychological and behavioral symptoms, such as agitation, which has been reported in up to 70% of patients. Agitation associated with dementia can negatively affect both the patient and caregivers quality of life. Caregiver burden can contribute significantly to burnout, which can result in premature institutionalization of the patient. Treating agitation associated with dementia has been a challenge for providers and current standards of care often have a slow onset of action and/or cause excessive sedation. There are currently no FDA-approved therapies for the treatment of dementia-related agitation, and off-label therapies have black box warnings associated with their use.

About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer, pancreatic cancer and advanced solid cancers in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com/.

Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the timing and data from clinical development initiatives and trials for BXCL501. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

Source: BioXcel Therapeutics, Inc.

More:
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia -...

Sight loss research needs urgent investment – The Guardian

As leading ophthalmologists and researchers we are joining the eye research charity Fight for Sight to call for urgent action on blindness in 2020 to address the research funding gap.

We know that serious sight loss doesnt discriminate it can affect anyone at any time and it is on the increase. Science can already do so much and with the advent of new gene therapies and stem cell treatments we are so close to outcomes that were not possible a decade ago. Yet so much more needs to be done to develop new universal treatments.

The main barrier is the lack of research funding. It is unacceptable that in 2020 only 1% of UK grant funding goes to eye research, even though more than 20% of people will be affected by serious sight loss in their lifetime. Blindness can have a huge impact on peoples mental health and ability to work, increasing costs on health systems and infrastructure.

In 2019 the WHO and UN general assembly both outlined that globally more investment is needed into sight loss and research. We are calling for the new government and its partners to agree a national plan on sight loss and a research agenda that will help to ensure that eye research gets the funding it badly needs. Please join us at fightforsight.org.uk and let 2020 be the year that we accelerate progress in beating blindness.

Prof Chris Hammond Frost chair of ophthalmology, Kings College London, Prof Alan Stitt Dean of innovation and impact, Queens University Belfast, Prof Alastair Denniston Consultant ophthalmologist, Birmingham University, Prof Alison Hardcastle Professor of molecular genetics, UCL Institute of Ophthalmology, Prof Lynda Erskine Chair in developmental neurobiology, Aberdeen University, Prof Jeremy Guggenheim Director of research, Cardiff University, Prof David Steel Consultant ophthalmologist, Newcastle University, Prof Chris Inglehearn Professor of molecular ophthalmology and neuroscience, Leeds University, Prof Timothy Jackson Consultant ophthalmic surgeon, Kings College London, Prof Rachael Pearson Professor of developmental neuroscience, UCL Institute of Ophthalmology, Prof Jessica Teeling Professor of Experimental Neuroimmunology, University of Southampton, Prof Colin Willoughby Professor of ophthalmology, Ulster University

Join the debate email guardian.letters@theguardian.com

Read more Guardian letters click here to visit gu.com/letters

Do you have a photo youd like to share with Guardian readers? Click here to upload it and well publish the best submissions in the letters spread of our print edition

Excerpt from:
Sight loss research needs urgent investment - The Guardian

While AI Is All the Rage, What Is Neuroscience Up To? – Fair Observer

Ever sincethe term artificial intelligence (AI) was coined in 1956, it has had a closerelationship with neuroscience. Initial concepts of building machines capableof logical thinking were derived from mathematical logic and informationtheory, but the driving force behind AI was the desire to mimic human brainfunction. Over the years, AI has captured our imagination by winning againsthumans in games like chess or Jeopardy.Yet how has neuroscience impacted our understanding of ourselves?

READ MORE

Going by media attention, it seems like AI is taking over the world. In fields as diverse as speech and image recognition, factory automation, stock trading and fraud detection, AI is pushing the envelope every day. It is being considered the backbone of the impending Fourth Industrial Revolution, which has spawned fears of large-scale disappearance of blue-collar and even white-collar jobs, coupled with predictions of global social unrest. Henry Kissinger, Bill Gates and Elon Musk, among others, have voiced their concerns about the ethical and moral quandaries posed by AI, but a closer examination reveals that advances in neurosciences have more profound implications for humanity.

In theshort run, artificial intelligence has outpaced our understanding of the brainbecause AI was built from the ground up, while brain research is primarilyreverse engineering. Our ever-expanding ability to pack more and moretransistors building blocks of digital circuits in increasingly smallerdevices has allowed AI researchers to build powerful, number-crunching machines.And an explosion of connectivity has ensured easy availability of informationacross the globe, making it easy to build intelligent machines.

On theother hand, each adult human brain has roughly 100 billion neurons; each one ofthem connected to, on average, 1,000 neurons. They communicate by way ofbiochemically generated electrical signals, which are more subtle or noisy thanthose flowing through man-made electronic circuits. We can use MRIs and CATscans to glean some information about brain function, but they do not providecellular-level detail, depriving us of critical details of informationprocessing abilities of neuronal networks.

Nonetheless, several new techniques are giving us unprecedented access to the inner workings of brain circuits. Simultaneous recordings from an array of microscopic probes allow us to observe the electrical activity of a group of neighboring neurons. Functional MRI scans, while performing cognitive tasks, tell us which parts of the brain are used to perform the task. Cellular imaging illuminates the neurons that are electrically active almost instantaneously as the brain is performing various tasks, allowing us to see how information flows to and from various parts of the brain in real-time. And optogenetics enables us to go one step further. Otherwise, light-insensitive neurons can now be genetically modified to make them light-sensitive.

Once thatis achieved, every time we shine light on those neurons, which is typically alaser, they become electrically active. Observing the behavior of the animalwhile activating specific parts of the brain can help us understand the rolesthey play. Together, these techniques are opening up a Pandoras box regardingour understanding of human ethics, politics and our belief in free will.

In the ongoing debate about Harvard Universitys bias against Asian Americans in their admission policy, documents revealed that Harvard consistently rates Asian Americans lower than others on personal traits like courage and likability in spite of their higher-than-average scores in SATs and ACTs. These standardized tests presumably assess attention and working memory capabilities, claiming that the scores are reliable predictors of future success.

Neuroscience might soon provide better assessment tools. Numerous studies have already established that areas like the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) play a critical role in tasks that demand high levels of attention and working memory. Researchers have also demonstrated that mindfulness practices like meditation can enhance the structure and function of ACC and DLPFC. Furthermore, they might even boost SAT scores.

It is anopen secret that cultural affinity for rote learning and long hours of practicehelp Asian Americans ace SATs and ACTs. If tomorrows brain scans establishthat the size and/or activity of ACC and DLPFC in simpler tasks are betterpredictors of future success, they might obviate the need for such gruelingtests. The outcome of such scans could take away the advantage of AsianAmericans in test scores or solidify their claims at a biological level. Inthat case, it is worth pondering whether brain scans should be used by futureadmissions committees.

Neuroscience is creating several such ethical dilemmas, but perhaps its effect on our understanding of monogamy is the most intriguing. A series of experiments on prairie voles and montane voles both rodent species suggests that preference for single vs. multiple sexual partners might be rooted in brain chemistry. While the two rodent species are genetically almost identical, prairie voles are monogamous and montane voles are promiscuous.

A highlevel of oxytocin is observed after copulation in both the species, and it isfamously known as the cuddling hormone, leading to lasting pair bonds betweenmates. However, only prairie voles have the receptors, or molecular detectors,to sense those high levels. Drawing inferences about human behavior based onstudies of voles might be a leap of faith today, but imagine the societaloutrage if it is established that your genes and brain chemistry determine yoursexual behavior.

Ourpolitics is another area that neuroscience has started shedding light on. Eversince the US presidential election in 2016, much has been said about Russiansusing social media to spread disinformation and polarize the electorate. Whatif brain scans can predict your political leanings better than tracking youronline behavior?

Some of the earliest neuroscientific studies of politics showed that, once again, the structure of ACC and its electrical activity during a specific cognitive task predicted the political leanings of study subjects with reasonable accuracy. In another study, conservatives give more weight to negative stimuli than positive ones compared to liberals. Several experiments have strengthened the conclusions, so much so that brain responses to a single disgusting, non-political visual stimulus were sufficient to accurately predict the volunteers political leaning. If casual brain scans become affordable and political consultants get access to them, legally or otherwise, we will enter a whole new era of political messaging, microtargeting and controlling masses.

Almost all of these insights are based on passive brain scans or behavioral observations. By giving us the ability to directly control brain activity, optogenetics is fundamentally altering our sense of who we are. In 2008, neuroscientists at Stanford University demonstrated how genetically modifying a specific part of a mouse brain to make it light-sensitive, and then shining a light on it, allows us to control when it runs with a flip of a switch. A more recent study at Yale University showed that aggressive, predatory behavior in mice can similarly be controlled with a switch.

Suchexperiments might be an affront to our belief in free will, but it is scarierto imagine a future in which brains of soldiers are controlled to have their killmode on during war and off when not on the battlefield. If we go a stepfurther to discuss who should control such switches, it threatens ourprevailing understanding of personal responsibility and rules of engagement ininternational conflicts.

AI poses achallenge to our professional lives, but neuroscience goes to the heart of whowe are as ethical, political and free-thinking creatures. To avoid large-scalesocial disruption, the adoption of AI might be easier to contain, but under theguise of social harmony, authoritarian leaders of tomorrow might find the toolsof neuroscience too tempting to resist.

The views expressed in this article are the authors own and donot necessarily reflect Fair Observers editorial policy.

Here is the original post:
While AI Is All the Rage, What Is Neuroscience Up To? - Fair Observer

These Breakthroughs Made the 2010s the Decade of the Brain – Singularity Hub

I rarely use the words transformative or breakthrough for neuroscience findings. The brain is complex, noisy, chaotic, and often unpredictable. One intriguing result under one condition may soon fail for a majority of others. Whats more, paradigm-shifting research trends often require revolutionary tools. When were lucky, those come once a decade.

But I can unabashedly say that the 2010s saw a boom in neuroscience breakthroughs that transformed the field and will resonate long into the upcoming decade.

In 2010, the idea that wed be able to read minds, help paralyzed people walk again, incept memories, or have multi-layered brain atlases was near incomprehensible. Few predicted that deep learning, an AI model loosely inspired by neural processing in the brain, would gain prominence and feed back into decoding the brain. Around 2011, I asked a now-prominent AI researcher if we could automatically detect dying neurons in a microscope image using deep neural nets; we couldnt get it to work. Today, AI is readily helping read, write, and map the brain.

As we cross into the next decade, it pays to reflect on the paradigm shifts that made the 2010s the decade of the brain. Even as a boo humbug skeptic Im optimistic about the next decade for solving the brains mysteries: from genetics and epigenetics to chemical and electrical communications, networks, and cognition, well only get better at understanding and tactfully controlling the supercomputer inside our heads.

Weve covered brain-computer interfaces (BCIs) so many times even my eyes start glazing over. Yet I still remember my jaw dropping as I watched a paralyzed man kick off the 2014 World Cup in a bulky mind-controlled exosuit straight out of Edge of Tomorrow.

Flash forward a few years, and scientists have already ditched the exosuit for an implanted neural prosthesis that replaces severed nerves to re-establish communication between the brains motor centers and lower limbs.

The rise in BCIs owes much to the BrainGate project, which worked tirelessly to decode movement from electrical signals in the motor cortex, allowing paralyzed patients to use a tablet with their minds or operate robotic limbs. Today, prosthetic limbs coated with sensors can feed back into the brain, giving patients mind-controlled movement, sense of touch, and an awareness of where the limb is in space. Similarly, by decoding electrical signals in the auditory or visual cortex, neural implants can synthesize a persons speech by reconstructing what theyre hearing or re-create images of what theyre seeingor even of what theyre dreaming.

For now, most BCIsespecially those that require surgical implantsare mainly used to give speech or movement back to those with disabilities or decode visual signals. The brain regions that support all these functions are on the surface, making them relatively more accessible and easier to decode.

But theres plenty of interest in using the same technology to target less tangible brain issues, such as depression, OCD, addiction, and other psychiatric disorders that stem from circuits deep within the brain. Several trials using implanted electrodes, for example, have shown dramatic improvement in people suffering from depression that dont respond to pharmaceutical drugs, but the results vary significantly between individuals.

The next decade may see non-invasive ways to manipulate brain activity, such as focused ultrasound, transcranial magnetic or direct current stimulation (TMS/tDCS), and variants of optogenetics. Along with increased understanding of brain networks and dynamics, we may be able to play select neural networks like a piano and realize the dream of treating psychiatric disorders at their root.

Rarely does one biological research field get such tremendous support from multiple governments. Yet the 2010s saw an explosion in government-backed neuroscience initiatives from the US, EU, and Japan, with China, South Korea, Canada, and Australia in the process of finalizing their plans. These multi-year, multi-million-dollar projects focus on developing new tools to suss out the brains inner workings, such as how it learns, how it controls behavior, and how it goes wrong. For some, the final goal is to simulate a working human brain inside a supercomputer, forming an invaluable model for researchers to test out their hypothesesand maybe act as a blueprint for one day reconstructing all of a persons neural connections, called the connectome.

Even as initial announcements were met with skepticismwhat exactly is the project trying to achieve?the projects allowed something previously unthinkable. The infusion of funding provided a safety blanket to develop new microscopy tools to ever-more-rapidly map the brain, resulting in a toolkit of new fluorescent indicators that track neural activation and map neural circuits. Even rudimentary simulations have generated virtual epilepsy patients to help more precisely pinpoint sources of seizures. A visual prosthesis to restore sight, a memory prosthesis to help those with faltering recall, and a push for non-invasive ways to manipulate human brains all stemmed from these megaprojects.

Non-profit institutions such as the Allen Institute for Brain Science have also joined the effort, producing map after map at different resolutions of various animal brains. The upcoming years will see individual brain maps pieced together into comprehensive atlases that cover everything from genetics to cognition, transforming our understanding of brain function from paper-based 2D maps into multi-layered Google Maps.

In a way, these national programs ushered in the golden age of brain science, bringing talent from other disciplinesengineers, statisticians, physicists, computer scientistsinto neuroscience. Early successes will likely drive even more investment in the next decade, especially as findings begin translating into actual therapies for people who dont respond to traditional mind-targeting drugs. The next decade will likely see innovative new tools that manipulate neural activity more precisely and less-invasively than optogenetics. The rapid rise in the amount of data will also mean that neuroscientists will quickly embrace cloud-storage options for collaborative research and GPUs and more powerful computing cores to process the data.

First, brain to AI. The physical structure and information flow in the cortex inspired deep learning, the most prominent AI model today. Ideas such as hippocampal replaythe brains memory center replays critical events in fast forward during sleep to help consolidate memoryalso benefit AI models.

In addition, the activation patterns of individual neurons merged with materials science to build neuromorphic chips, or processors that function more like the brain, rather than todays silicon-based chips. Although neuromorphic chips remain mainly an academic curiosity, they have the potential to perform complicated, parallel computations at a fraction of the energy used by processors today. As deep neural nets get ever-more power hungry, neuromorphic chips may present a welcome alternative.

In return, AI algorithms that closely model the brain are helping solve long-time mysteries of the brain, such as how the visual cortex processes input. In a way, the complexity and unpredictability of neurobiology is shriveling thanks to these computational advancements.

Although crossovers between biomedical research and digital software have long existedthink programs that help with drug designthe match between neuroscience and AI is far stronger and more intimate. As AI becomes more powerful and neuroscientists collaborate outside their field, computational tools will only unveil more intricacies of neural processing, including more intangible aspects such as memory, decision-making, or emotions.

I talk a bunch about the brains electrical activity, but supporting that activity are genes and proteins. Neurons also arent a uniform bunch; multiple research groups are piecing together a whos who of the brains neural parts and their individual characteristics.

Although invented in the late 2000s, technologies such as optogenetics and single-cell RNA sequencing were widely adopted by the neuroscience community in the 2010s. Optogenetics allows researchers to control neurons with light, even in freely moving animals going about their lives. Add to that a whole list of rainbow-colored proteins to tag active cells, and its possible to implant memories. Single-cell RNA sequencing is the queen bee of deciphering a cells identity, allowing scientists to understand the genetic expression profile of any given neuron. This tech is instrumental in figuring out the neuron populations that make up a brain at any point in timeinfancy, youth, aging.

But perhaps the crown in new tools goes to brain organoids, or mini-brains, that remarkably resemble those of preterm babies, making them excellent models of the developing brain. Organoids may be our best chance of figuring out the neurobiology of autism, schizophrenia, and other developmental brain issues that are difficult to model with mice. This decade is when scientists established a cookbook for organoids of different types; the next will see far more studies that tap into their potential for modeling a growing brain. With hard work and luck, we may finally be able to tease out the root causes of these developmental issues.

Image Credit: NIH

Read the original post:
These Breakthroughs Made the 2010s the Decade of the Brain - Singularity Hub

Study ties gene active in developing brain to autism – Spectrum

Puzzling injury: Some children who carry variants in a gene called ZNF292 have injured blood vessels in their brains.

Mutations in a gene called ZNF292 lead to a variety of developmental conditions, including autism and intellectual disability, according to a new study1.

ZNF292 encodes a protein that influences the expression of other genes. It is highly expressed in the developing human brain, particularly in the cerebellum, an area that controls voluntary movement and contributes to cognition. However, its function in neurodevelopment is unknown.

Scientists first linked ZNF292 to intellectual disability in a 2012 study. A 2018 analysis of five ZNF292 variants tied the gene to autism, but the work was preliminary2.

In the new study, researchers identified 28 people who have mutations in ZNF292. The participants come from six countries and are between 10 months and 24 years old. The group carries a total of 24 mutations in the gene, 23 of which are spontaneous meaning that they were not inherited from a parent.

The sheer number of families and children that have been identified so far has been quite high, says Ghayda Mirzaa, lead investigator and assistant professor of genetic medicine at Seattle Childrens Hospital in Washington.

All but one of the participants have intellectual disability. In total, 17 of the participants are suspected or confirmed to have autism and 9 are suspected or confirmed to have attention deficit hyperactivity disorder. All but two have speech delays, and four have had language regression or are minimally verbal.

Mirzaas team found an additional 15 people with mutations in the gene from 12 families. However, the data from these people were incomplete, so the researchers had to exclude them from the analysis. The team has connected with at least 10 other mutation carriers in the six weeks since the study was published in Genetics in Medicine.

The researchers have used their data to classify a new condition. However, it may be premature to call it a syndromic form of autism or intellectual disability, says Holly Stessman, assistant professor of pharmacology and neuroscience at Creighton University in Omaha, Nebraska, who was not involved in the work.

People with ZNF292 variants have a broad spectrum of physical traits. For instance, 11 of the people in the study have growth abnormalities such as short stature; 10 have low muscle tone; and 3 have stiff or mixed muscle tone. The researchers had access to magnetic resonance imaging scans for 17 of the participants: 9 show brain abnormalities such as atypically shaped regions, and 3 of those 9 appear to have blood-vessel injuries in the brain.

Nearly half of the participants also have unusual facial characteristics, including an undersized jaw or eyes that are unusually far apart. Vision problems, such as involuntary eye movement or crossed eyes, affect nine people in the group. Less common facial differences include prominent incisors and protruding ears.

Autism genes are often linked to a wide range of characteristics, says Santhosh Girirajan, associate professor of biochemistry and molecular biology at Pennsylvania State University, who was not involved in the study. Variability has become the rule now, rather than the exception, he says.

Mirzaa says her group plans to study more individuals with variants in ZNF292, and to investigate the genes function.

See the original post here:
Study ties gene active in developing brain to autism - Spectrum